✔ 100% Authentic Product
👁️ Currently Viewing 509
Eltropag 25 | 1 Strip
Eltropag 25 is indicated for the treatment of:
- Chronic immune (idiopathic) thrombocytopenic purpura (ITP) in adult and pediatric patients who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
- Thrombocytopenia in chronic Hepatitis C virus (HCV) infection allows the initiation and maintenance of interferon-based therapy.
- Severe aplastic anemia (SAA) in adults who are refractory to other treatments or as first-line therapy in combination with immunosuppressants.
- If a dose is missed, skip it and take the next dose at the regular time. Do not double the dose.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Cash on Delivery - All over Bangladesh
Regular Delivery - 12-24 Hours, Dhaka City*- Regular Delivery - 24-48 Hours, All Over Bangladesh*
ফ্রি ডেলিভারি! - ১৪৯৯ টাকা+ অর্ডারে ঢাকা
শহরে ।
✅ Description:
Eltrombopag is a small-molecule agonist of the thrombopoietin (TPO) receptor. It binds to the transmembrane domain of the TPO receptor (c-Mpl) on megakaryocyte precursors in the bone marrow, promoting megakaryocyte proliferation and differentiation, ultimately increasing platelet production.
✔️ Common Side Effects
- Gastrointestinal: Nausea, vomiting, diarrhea
- Infections: Upper respiratory tract infection, urinary tract infection
- Liver: Elevated liver enzymes (ALT, AST)
- Musculoskeletal: Muscle pain (myalgia)
- Others: Headache, fatigue, rash, itching, insomnia
✔️ Dosage & Administration
General Instructions:
- Take on an empty stomach: either 1 hour before or 2 hours after food.
- Avoid dairy products, antacids, or mineral supplements (e.g. calcium, magnesium, iron, aluminum, selenium, zinc) within 4 hours before or after dosing.
Adult Dose:
- Chronic ITP & HCV-related thrombocytopenia: Start with 50 mg once daily; adjust to maintain platelet counts ≥50×10⁹/L. Max 100 mg/day.
- Severe Aplastic Anemia (SAA): Start with 50 mg once daily; titrate based on platelet response. Do not exceed 150 mg/day.
- Hepatic impairment: Avoid in patients with cirrhosis unless the benefits outweigh risks (e.g. portal vein thrombosis).
Pediatric Dose:
- Ages 6 years and older: 50 mg once daily.
- Ages 1–5 years: 25 mg once daily.
Dose is adjusted based on platelet count response.
✔️ Drug Interactions
- Reduced absorption with antacids, calcium-containing foods, or supplements with polyvalent cations.
- Increased eltrombopag levels with fluvoxamine; decreased with rifampicin, lopinavir/ritonavir.
- Additive effects with HMG-CoA reductase inhibitors (monitor for toxicity).
High-fat meals significantly reduce bioavailability; take on an empty stomach.
✔️ Pregnancy & Lactation
Pregnancy Category: Not recommended. Animal studies show fetal toxicity. Use only if the benefits clearly outweigh the risks.
Lactation: Not advised. Unknown if excreted in human milk, but detected in animal studies.
✔️ Precautions
- Monitor platelet counts, liver enzymes, and blood chemistry regularly.
- Caution in patients with hepatic impairment, as the risk of portal vein thrombosis may increase.
- Discontinuation may cause rebound thrombocytopenia, increasing the bleeding risk.
- Risk of bone marrow reticulin formation and potential fibrosis.
- Possible increased risk of thromboembolism at high platelet levels.
- Monitor for disease progression in hematologic malignancies.
- Use effective contraception in females of reproductive potential during treatment and for at least 7 days after stopping therapy.
✔️ Storage Conditions
- Store in a cool, dry place below 25°C.
- Protect from light and moisture.
- Keep out of reach of children.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.
